Thrombolytic

ApprovedSmall molecule

FFaculty Hospital Kralovske Vinohrady

Thrombolytic is one of 77 small molecule programs targeting Pulmonary Embolism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismActive, not recruiting

COVID-19Active, not recruiting

Pulmonary EmbolismApproved

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Thrombolytic

FFaculty Hospital Kralovske Vinohrady

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Singulair

AstraZeneca

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Aldactone

Pfizer

Preclinical

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalRecruiting

Pulmonary Embolism

NCT05493163

Clinical

Trials by Indication[1]

STEMI1 trial

The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI

Withdrawn·—··NCT03267199

Pulmonary Embolism1 trial

Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism

Recruiting·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT05493163·558 enrolled

COVID-191 trial

Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.

Unknown status·YYa-Wei Xu·N/A·NCT05354128·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Thrombolytic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thrombolytic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thrombolytic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Faculty Hospital Kralovske Vinohrady company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFaculty Hospital Kralovske Vinohrady

Thrombolytic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

STEMI1 trial

Pulmonary Embolism1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News